Business Context and Reporting Period
Company: Sheffield Pharmaceuticals, Inc. (Note: Request metadata listed "Theriva Biologics," but the filing text identifies the registrant as Sheffield Pharmaceuticals, Inc.)
Reporting Period: Quarter ended March 31, 1999
Status: Development stage enterprise focused on pulmonary drug delivery technologies (Metered Solution Inhaler and Aerosol Drug Delivery System).
Operations: The Company has generated minimal operating revenue and sustained significant net operating losses. It relies on strategic alliances (Elan, Zambon, Siemens) and external funding to continue operations.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 | Inception to Mar 31, 1999 |
|---|---|---|---|
| Total Revenues | $21,877 | $953 | $1,895,977 |
| Net Loss | $(1,162,656) | $(2,263,048) | $(55,800,906) |
| Net Loss per Share (Basic/Diluted) | $(0.04) | $(0.17) | $(8.27) |
| Cash and Cash Equivalents | $1,908,615 | $7,876 | N/A |
| Net Cash Used (Operating/Dev) | $(1,092,641) | $(450,092) | $(49,974,817) |
| Total Assets | $2,307,886 | N/A | N/A |
| Total Liabilities | $2,689,659 | N/A | N/A |
| Stockholders' Equity (Deficiency) | $(381,773) | N/A | N/A |
Debt and Liquidity:
- Convertible Promissory Note: $1,500,000 outstanding (Elan facility).
- Note Payable (Related Party): $104,145 (due May 1999).
- Sponsored Research Payable: $449,805.
- Liquidity: Cash balance of $1.9 million as of March 31, 1999. Management states ability to meet obligations through December 1999 is dependent on obtaining additional funding.
Material Changes vs. Prior Period
- Revenue: Total revenue increased to $21,877 from $953 in Q1 1998, driven entirely by higher interest income ($21,877 vs. $953) due to increased cash balances. No sublicense revenue was generated in the quarter.
- Net Loss: Net loss improved significantly to $(1.16) million from $(2.26) million in Q1 1998.
- Research & Development (R&D): R&D expenses decreased by $954,062 to $654,979. This reduction is primarily due to the shifting of development responsibility for respiratory applications of the MSI to partner Zambon.
- General & Administrative (G&A): G&A expenses decreased by $112,827 to $499,663, attributed to lower compensation costs from a reduced employee count.
- Interest Expense: Decreased to $29,891 from $42,470 following the conversion of Series A Preferred Stock and Convertible Subordinated Debentures into Common Stock during 1998.
Outlook, Risks, and Management Commentary
Outlook and Capital Resources:
- The Company expects to incur additional costs for ongoing R&D, preclinical/clinical testing, and patent enforcement.
- Management believes it will require additional funds to meet future costs, to be obtained through equity/debt offerings or collaboration agreements.
- Commitments: Committed to fund an additional $1,729,000 for pulmonary delivery system development subsequent to March 31, 1999.
- Financing Facilities: $500,000 remaining available under the Elan convertible note. Zambon provided a $1 million interest-free advance in May 1999 (repayable 2002 or upon milestones).
Risks and Contingencies:
- Going Concern: The financial statements are prepared on a going concern basis, but there is no assurance the Company will generate sufficient revenue to be profitable or obtain necessary funding.
- Year 2000 Compliance: Estimated cost less than $25,000. Substantially all software is compliant; hardware upgrades expected by Q2 1999. Risks remain regarding third-party vendors (universities/labs).
- Commercialization: No assurance that technologies will be successfully commercialized or that revenues will fund operations.
Investor Verification Checklist
- Cash Runway: Verify if the $1.9 million cash balance is sufficient to cover the committed $1.73 million development funding plus ongoing operating losses through the end of 1999.
- Debt Maturity: Confirm the repayment status of the $104,145 related party note due May 1999.
- Partnership Reliance: Assess the risk exposure if partners (Zambon, Elan) fail to meet their funding or development obligations.
- Capital Raises: Monitor for announcements of new equity or debt offerings required to sustain operations beyond December 1999.
- Year 2000 Status: Verify completion of hardware upgrades and third-party compliance assessments by July 1999.